| Code | CSB-RA858415MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Blosozumab, targeting sclerostin (SOST), a glycoprotein secreted primarily by osteocytes in bone tissue. SOST functions as a negative regulator of bone formation by inhibiting the Wnt signaling pathway, which is essential for osteoblast differentiation and activity. By binding to LRP5/6 co-receptors, sclerostin prevents Wnt-mediated bone formation, making it a critical regulator of bone mass and skeletal homeostasis. Dysregulation of SOST expression is associated with various bone disorders, including osteoporosis, sclerosteosis, and van Buchem disease.
Blosozumab is a humanized monoclonal antibody that was developed to neutralize sclerostin activity, thereby promoting bone formation through disinhibition of the Wnt pathway. This biosimilar antibody serves as a valuable research tool for investigating sclerostin biology, bone metabolism, and skeletal diseases. It enables researchers to explore the therapeutic potential of SOST inhibition and study the molecular mechanisms underlying bone remodeling and mineralization in various experimental models.
There are currently no reviews for this product.